Literature DB >> 2729538

[An infusion of THAM (trishydroxymethylaminomethane) as therapy to lower increased intracranial pressure in acute craniocerebral injuries].

E Pfenninger1, K H Lindner, F W Ahnefeld.   

Abstract

Despite of the use of all the current intensive care measures, some patients develop dangerously high intracranial pressures (ICP) after head injury. We have studied the use of THAM for the rapid control of dangerously high ICP in these patients. PATIENT AND METHODS. After all conventional methods of lowering ICP had been applied without sufficient effect, 1 mmol/kg body wt. THAM was given i.v. over a period of 10 min to ten patients with head injury. All patients were hyperventilated, sedated with thiopental (3-6 g/day), and the upper body was elevated to 30 degrees. The intracranial pressure and mean arterial pressure were monitored, arterial blood gas levels measured, and cerebral perfusion pressure (CPP) calculated. RESULTS. Our patients had a mean ICP of 37.4 Torr, which fell to 27.2 Torr within 10 min after the administration of THAM. The CPP rose from 46.5 to 56.3 Torr, no rebound was observed. There was no change in arterial blood gas values. DISCUSSION. Our study indicates that THAM not only decreases an elevated ICP, but also improves CPP. These results are of note because only patients with otherwise unresponsive increases in ICP were included.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2729538

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  3 in total

Review 1.  THAM for control of ICP.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

Review 2.  Osmotherapy for elevated intracranial pressure: a critical reappraisal.

Authors:  R Nau
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 3.  Guidelines for the treatment of acidaemia with THAM.

Authors:  G G Nahas; K M Sutin; C Fermon; S Streat; L Wiklund; S Wahlander; P Yellin; H Brasch; M Kanchuger; L Capan; J Manne; H Helwig; M Gaab; E Pfenninger; T Wetterberg; M Holmdahl; H Turndorf
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.